Changchun High-tech: Subsidiary approved for clinical trial of acellular pertussis combined vaccine with adsorption

Changchun High-tech announced on November 12th that its subsidiary Changchun Baik Biological Technology Co., Ltd. received the "Drug Clinical Trial Approval Letter" from the National Medical Products Administration for its adsorbedacellular pertussis combination vaccine, recommending approval to carry out clinical trials for the prevention of whooping cough, diphtheria, and tetanus.